Empagliflozin for the treatment of Type 2 diabetes

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 271-279

  Komala, Muralikrishna Gangadharan ^a   Mather, Amanda ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular; Empagliflozin; Renal proximal tubule; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADVERSE OUTCOME; AREA UNDER THE CURVE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; END STAGE RENAL DISEASE; FIRST PASS EFFECT; GLUCOSE OXIDATION; GLUCOSE URINE LEVEL; HEALTH CARE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; METABOLIC DISORDER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; REVIEW; STEADY STATE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84898917461     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.908703     Document Type: Review

References (49)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
2. Maruthur NM. The growing prevalence of type 2 diabetes: increased incidence or improved survival? Curr Diab Rep 2013; 13(6):786-94
3. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305(24):2532-9
4. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261(1):32-43
5. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22(1):104-12
6. Hummel CS, Lu C, Loo DD, et al. Glucose transport by human renal Na+/Dglucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011;300(1): C14-21
7. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):34-42
8. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/ SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92(2):158-69
9. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159(4):262-74
10. Ferrannini E, Solini A, SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8(8): 495-502
11. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9733):2223-33
12. Abdul-Ghani MA, Norton L, DeFronzo RA . Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012;12(3):230-8
13. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 mg. Rockville, MD: U.S. Food and Drug Administration; 2011. Available from: www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/drugs/ EndocrinologicandMetabolicDrugs AdvisoryCommittee/ucm262994.pdf
14. FDA Briefing Document. NDA 204042. Invokana (Canagliflozin) Tablets. Rockville, MD: U.S. Food and Drug Administration. Available from: www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ Endocrinologicand MetabolicDrugsAdvisoryCommittee/ ucm334550.pdf
15. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2013. [Epub ahead of print]
16. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304(2):F156-67
17. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60(3): 890-8
18. Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol 2013; 53(10):1028-38
19. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2013;28(3):213-19
20. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;4(2):331-45
21. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61(9):2199-204
22. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90
23. Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013;15(4):316-23
24. Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther 2013;35(3):226-35
25. Macha S, Mattheus M, Pinnetti S, et al. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig 2013;33(5):351-7
26. Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;16(3):215-22
27. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2013. [Epub ahead of print]
28. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15(8):721-8
29. Roden M WJ, Eilbracht J, Delafont B, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1(3):208-19
30. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15(12):1154-60
31. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36(11):3396-404
32. Rosenstock J JA, Wang F, Kim G, et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated Type 2 diabetes (T2DM). American diabetes association 73rd scientific sessions, Chicago, IL, USA; 2013
33. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013. [Epub ahead of print]
34. Hach T GJ, Salsali A, Kim G, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. In: American Diabetes Association 73rd Scientific sessions, Chicago, IL, USA; 2013
35. Mayoux E LG, Mark M. Durable effect of empagliflozin on glucose homeostasis independent of the disease state of type 2 diabetes ZDF rats. In: American Diabetes Association 73rd Scientific sessions, Chicago, IL, USA, 2013
36. Ferrannini E ME, Frascerra S, Baldi S, et al. Metabolic response to sodium-glucose transporter 2 (sglt2) inhibition with empagliflozin in patients with type 2 diabetes (T2D). In: The American Diabetes Association 73rd Scientific session, Chicago, IL, USA; 2013
37. Barnett AH MA, Manassie J, Jones R, et al. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and Renal Impairment (RI). In: American Diabetes Association 73rd Scientific sessions, Chicago, IL, USA; 2013
38. Kim G GJ, Salsali A, Hach T, et al. Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. In: American Diabetes Association 73rd Scientific sessions. Chicago, IL, USA, 2013
39. Kovacs C SV, Swallow R, Jones R, et al. Empagliflozin as add-on to pioglitazone with or without metformin improves glycemic control in patients with type 2 diabetes (T2DM). In: American Diabetes Association 73rd Scientific sessions, Chicago, IL, USA, 2013
40. Ferrannini E PE, Hach T, Woerle HJ, Broedl UC. Empagliflozin (empa), a sodium glucose cotransporter 2 (sglt2) inhibitor for 90 weeks provides sustained glycemic control and weight loss in patients with type 2 diabetes (t2dm). In: Annual Meeting of the AACE, Phoenix, AZ, USA; 2013
41. Woerle HJ KT, Haneda M, Inagaki N, et al. Safety and efficacy of empagliflozin monotherapy in a 52-week study in Japanese patients with type 2 diabetes mellitus. In: EASD Annual Meeting, Barcelona, Spain; 2013
42. Boehringer Ingelheim Pharmaceuticals. A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2010. NLM Identifier: NCT01131676. Available from: http://clinicaltrials. gov/show/ NCT01131676 [Last accessed 12 January 2014]
43. Ring A, Brand T, Macha S, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol 2013;12(1):70
44. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36(12):4015-21
45. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
46. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72
47. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
48. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373(9681): 2125-35
49. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26